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ABSTRACT 36 
The discovery of biomarkers of intake in nutritional epidemiological studies is essential 37 
in establishing an association between dietary intake (considering their bioavailability) 38 
and diet-related risk factors for diseases. The aim is to study urine and plasma phenolic 39 
and microbial profile by targeted metabolomics approach in a wine intervention clinical 40 
trial for discovering and evaluating food intake biomarkers.  41 
High-risk male volunteers (n=36) were included in a randomized, crossover intervention 42 
clinical trial. After a washout period, subjects received red wine or gin, or dealcoholized 43 
red wine over 4 weeks. Fasting plasma and 24-h urine were collected at baseline and 44 
after each intervention period. A targeted metabolomic analysis of 70 host and 45 
microbial phenolic metabolites was performed using UPLC-MS/MS. Metabolites were 46 
subjected to stepwise logistic regression to establish prediction models and received 47 
operation curves were performed to evaluate biomarkers.  48 
Prediction models based mainly on gallic acid metabolites, obtained sensitivity, 49 
specificity and area under the curve (AUC) for the training and validation sets of 50 
between 91% and 98% for urine and between 74% and 91% for plasma. Resveratrol, 51 
ethylgallate and gallic acid metabolite groups in urine samples also resulted in being 52 
good predictors of wine intake (AUC>87%). However, lower values for metabolites 53 
were obtained in plasma samples. The highest correlations between fasting plasma and 54 
urine were obtained for the prediction model score (r=0.6, P<0.001), followed by gallic 55 
acid metabolites (r=0.5-0.6, P<0.001). This study provides new insights into the 56 
discovery of food biomarkers in different biological samples.  57 
58 
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1 Introduction  59 
Biomarkers in epidemiological and clinical trials have to be indicators of exposure and 60 
must have several characteristics, including being robust, sensitive to changes, specific 61 
to the dietary source and biologically and physiologically understandable [1]. In the 62 
food research field, this means that biomarkers have to be an objective measure of 63 
intake and an evaluated indicator of food intervention [2]. There has been much in-64 
depth discussion concerning their ability to solve classical problems regarding 65 
estimating an index of quantitative exposure to individual food [1-3], and recently, 66 
identifying dietary patterns that may be related to major health benefits. Hence, there is 67 
an increased interest in biomarker research for the development of new functional 68 
foods, as well as for the validation of existing biomarkers [4]. Therefore, global 69 
metabolic approaches need to be carried out in order to evaluate the role of individual or 70 
groups of metabolites in the discrimination of selected food consumption. 71 
After consumption of polyphenols, beneficial health effects in the prevention of diseases 72 
have been widely analysed in in vivo and in vitro studies [5-7]. In particular, the 73 
consumption of grape-derived products such as red wine (RW) and dealcoholized RW 74 
(DRW) has been associated with a protective effect against cardiovascular diseases, 75 
possibly through their anti-inflammatory and antihypertensive activities [5, 8]. These 76 
associations were first linked to phytochemicals found in foods, which could exert their 77 
biological activity. However, in recent years there has been increasing attention paid to 78 
the metabolites formed in the organism, especially those formed by microbiota, due to 79 
their role in the prevention of some diseases such as obesity and diabetes [9, 10]. This 80 
supposes an increase in the variety of metabolites found in biofluids after consumption, 81 
and therefore an increased number of possible food biomarkers [11]. Moreover, new 82 
targeted and untargeted approaches have also increased the range of metabolites found 83 
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in biofluids, allowing the use of metabolomic tools for a new approach in biomarker 84 
research. In the case of RW, resveratrol metabolites have been described as being good 85 
biomarkers of wine intake [12, 13], and gallic acid has also been suggested as a marker, 86 
due to its increased excretion after wine consumption [14]. Both compounds were 87 
determined in 24-h urine. This sample has been suggested as being better for biomarker 88 
determination than others but since it is difficult to obtain in large epidemiological 89 
studies [1, 12-14], other samples such as fasting plasma need to be assessed for their 90 
potential to identify biomarkers. 91 
Here, we study the phenolic and microbial profile by a targeted metabolomics approach 92 
in a wine intervention clinical trial for the discovery and evaluation of biomarkers of 93 
wine intake considering both fasting plasma and 24-h urine samples. 94 
 95 
96 
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2 Materials and Methods 97 
2.1 Subjects and study design 98 
Thirty-six volunteers were included for the study of the targeted phenolic metabolite 99 
profile. The study was an open, randomized, crossover and controlled clinical 100 
intervention trial comprising three 4-week periods [5]. Baseline characteristics of 101 
participants and inclusion and exclusion criteria are given in detail in the Supporting 102 
Information and Supporting Information Table S1. After following a 15-day run-in 103 
period free of grape-derived products and alcoholic beverages, subjects were requested 104 
to consume 272 mL of RW (30 g ethanol/day), 272 mL of DRW and 100 mL of gin (30 105 
g ethanol/day) every day for 4 weeks, following the same background diet. Fasting 106 
blood samples (n=33) and 24-h urine samples (n=36) were collected after each 107 
intervention period and immediately stored at −80 °C until analysis. The Institutional 108 
Review Board of the hospital approved the study protocol. All participants gave written 109 
consent before participation in the study. This trial was registered in the Current 110 
Controlled Trials at the International Standard Randomized Controlled Trial Number 111 
Register, at controlled-trials.com, as ISRCTN88720134. 112 
 113 
2.2 Chemicals and reagents 114 
Chemical reagents and solvents used in this study are detailed in Supporting 115 
Information. 116 
 117 
2.3 Red wine, dealcoholized red wine and gin 118 
The RW and DRW used in this study were made with the Merlot grape variety, from the 119 
Penedès appellation (Catalonia, Spain). No differences in phenolic composition were 120 
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found between wines (Supporting Information Table S2) [15]. Xoriguer gin was used to 121 
ensure the same alcoholic consumption as the RW period. 122 
 123 
2.4 Sample extraction 124 
The targeted analyses of microbial-derived and conjugated metabolites were performed 125 
using solid-phase extraction. Oasis® MCX and HLB 96-well plates (Waters, Milford, 126 
Massachusetts) were used in hydrolyzed and non-hydrolyzed samples, respectively, as 127 
previously described [16-18]. Briefly, urine and plasma samples (1 mL) were loaded 128 
onto the conditioned cartridge plate. Then the cartridges were washed and analytes were 129 
eluted with methanol or acidified methanol (0.1% formic acid), respectively. Eluates 130 
from both extraction methods were evaporated to dryness under a gentle stream of 131 
nitrogen gas [17]. Residues were reconstituted with 100 µL of taxifolin (1.64 µmol/L) 132 
dissolved in mobile phase [16, 18].  133 
 134 
2.5 UPLC-MS/MS analysis  135 
The analysis of metabolites in urine and plasma was performed by UPLC-MS/MS 136 
equipped with a binary solvent manager and a refrigerated autosampler plate (Waters 137 
Acquity UPLC system, Milford, MA, USA), coupled to an AB Sciex API 3000 triple 138 
quadrupole mass spectrometer equipped with a turbo ion spray, in a negative 139 
electrospray ionization mode (PE Sciex). An Acquity UPLC BEH C18 (Milford, MA, 140 
USA) (1.7 µm, 2.1 mm × 5 mm), using a pre-filter, working at 40 °C with 0.5 mL/min 141 
with an injection volume of 5 μL, was used as described before [16]. Mobile phase A 142 
(0.1% formic acid) and B (0.1% formic acid in acetonitrile) were used at a flow rate of 143 
500 μL/min with the following proportions (v/v) of phase A [t(min),%A]: (0,92); 144 
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(2.5,50); (2.6,0); (3,0); (3.1,92); (3.5,92). The MS/MS parameters used were as 145 
previously described [16, 17]. 146 
 147 
2.6 Quantitative analysis 148 
For quantification purposes, data were collected using the multiple reaction monitoring 149 
(MRM) mode (Table 1 and Table 2) with a dwell time of 10 ms. When commercial 150 
standards were not available, concentrations were quantified using the most similar 151 
compound standard curve. Results were expressed as their equivalents [16]. The mean 152 
recovery of analytes ranged from 87% to 109%, and accuracy and precision of analytes 153 
at different concentrations were <15% [16, 17]. 154 
 155 
2.7 Statistical analysis  156 
Two statistical programs for data analysis were used: the MetaboAnalyst Web-based 157 
platform [19] and IBM SPSS Statistics software program for Windows version 20 158 
(Chicago, IL). The overall approach is described with the following steps: i) Data 159 
normalization of quantified phenolic metabolites was performed by a cube root 160 
transformation and a range scaling of the data; ii) This data retrieved an unsupervised 161 
segregation by principal component analysis (PCA) and hierarchical clustering analysis; 162 
iii) ANOVA for repeated measures was used to compare changes in phenolic 163 
metabolites in plasma and urine after intervention treatments (Bonferroni post hoc test); 164 
iv) Among the metabolites that displayed significantly different levels between wine 165 
interventions and baseline or gin period, a binary stepwise logistic regression analysis 166 
was performed to assess which metabolite combination predicted the wine intervention. 167 
For this purpose, 80% of random samples of wine interventions and baseline or gin 168 
periods were used as a training set, in which the logistic regression model was 169 
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calculated, and the remaining samples of each group (20%) were used as a validation 170 
set; v) The sensitivity, specificity and area under the curve (AUC) of the model were 171 
compared with parameters of phenolic metabolite groups in the whole population 172 
through a receiver operating characteristic (ROC) curve. The phenolic metabolite 173 
groups in urine and plasma are described in Supporting Information Table S3. In 174 
addition to the metabolites analysed in this study, resveratrol data from previous 175 
analysis [15] were  included to be evaluated and compared, since resveratrol has already 176 
been described as a wine intake biomarker [12, 13]. 177 
The optimal cut-off for the ROC curves was determined through the identification of the 178 
shortest distance to the optimal point (0,1) for which specificity and sensitivity was 179 
calculated. 180 
To estimate the association between fasting plasma and 24-h urine in the prediction 181 
models and within the phenolic metabolite groups, the Spearman correlation 182 
coefficients were calculated. Statistical significance was defined as P ≤ 0.05.183 
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3 Results 184 
3.1 Urine and plasma analysis of targeted polyphenol metabolomic pattern 185 
Nineteen individual metabolites and conjugates of (epi)catechin, methyl(epi)catechin 186 
and dihydroxyphenyl-γ-valerolactone (DHPV), and 10 phenolic acids including 187 
methylgallic sulfate and the group of total resveratrol metabolites significantly increased 188 
in urine after RW or DRW interventions compared to the baseline or gin periods (Table 189 
1). Only ethylgallate metabolites showed a statistically significant difference between 190 
both wine periods of intake. The plasma metabolites that increased after the wine 191 
interventions in relation to the baseline or gin periods included 10 phenolic acids, such 192 
as gallic acid and DHPV and their conjugates (Table 2).   193 
The PCA differentiated easily between urinary samples from RW and DRW 194 
interventions and samples from those in the baseline or gin period (Supporting 195 
Information Fig. S1A). PC1 explained 41.9% of the total variance while PC2 explained 196 
7.6% of the total variance, where the loading plot showed that gallic acid, ethylgallate 197 
and resveratrol metabolites were mainly responsible for this difference (data not 198 
shown). The clustering analysis executed by the heat map compared the metabolites of 199 
the participants in the four intervention periods. This was used as a first approach to 200 
assess the possible use of phenolic groups as biomarkers of wine consumption. A 201 
progression in the strongest discriminatory signals was observed in the heat map 202 
(Supporting Information Fig. S1B). The strongest discriminatory signals were observed 203 
for resveratrol, gallic acid and ethylgallate metabolites, followed by (epi)catechin and 204 
valerolactone metabolites, and the least discriminatory signals were those of phenolic 205 
acids.  206 
 207 
3.2 Evaluation of food intake biomarkers 208 
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The applicability of a logistic regression model involving multiple metabolites was 209 
examined to find the best markers of wine consumption in hydrolyzed and non-210 
hydrolyzed fasting plasma and 24-h urine samples from a clinical study in the training 211 
set. Metabolites that displayed significantly different levels between wine interventions 212 
and the baseline or gin period were subjected to a stepwise variable selection method. 213 
The results of the model for each type of sample are shown in Table 3. Metabolites 214 
included in the models did not display multicollinearity (data not shown). Both groups 215 
of resveratrol (resveratrol biomarker and microbial resveratrol metabolites) showed 216 
AUC over 96% and were analyzed only in non-hydrolyzed urine samples. Therefore, 217 
they were excluded from the logistic regression to be able to compare models with the 218 
same metabolites between different samples. The validity of the model was confirmed 219 
with the validation set and then applied to the whole population. The results of 220 
sensitivity, specificity and AUC for the model were higher than 92% and 74% for urine 221 
and fasting plasma samples, respectively, among training and validation sets, and for the 222 
whole population (Table 4). The global performance of the model for each kind of 223 
sample considering the whole population was depicted in the ROC curves (Supporting 224 
Information Fig. S2) and compared with the results obtained for the different phenolic 225 
groups (Table 4 and Supporting Information Fig. S2). In hydrolyzed urine, the best 226 
sensitivity, specificity and AUC were obtained for the model, followed by ethylgallate. 227 
In non-hydrolyzed urine samples, the groups of ethylgallate, methylgallic and 228 
resveratrol metabolites (AUC: 93–99%) resulted in being better discriminators of wine 229 
intake than (epi)catechin and DHPV metabolites (AUC: 76–86%). The best sensitivity 230 
and specificity were obtained for the model and for microbial resveratrol metabolites 231 
(cut-off value: 1424.19 µmol/24-h), and closely followed by the resveratrol biomarker. 232 
Plasma metabolites were weaker indicators of wine intake. Only the model in both 233 
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hydrolyzed and non-hydrolyzed samples and methylgallic sulfate in non-hydrolyzed 234 
samples had an AUC over 80%, which matched the results obtained in the prediction 235 
model.  236 
 237 
3.3 Correlations between fasting plasma and 24-h urine  238 
Correlations of individual metabolites, phenolic metabolite groups and the prediction 239 
model between 24-h urine and fasting plasma samples were performed (Table 5). The 240 
highest correlations were obtained for the prediction model score in both hydrolyzed 241 
and non-hydrolyzed samples (r=0.565 and 0.599, P<0.001, respectively) (Table 5 and 242 
Supporting Information Fig. S3), followed by the gallic acid metabolite group (r=0.451 243 
and 0.587, P<0.001, respectively). The group of flavan-3-ols and DHPV metabolites 244 
had lower but significant correlation values (r=0.4, P<0.001) in non-hydrolyzed 245 
samples. 246 
247 
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4 Discussion  248 
This is the first study in which phenolic metabolites from wine intake have been 249 
systematically evaluated and trialled in quantitative approach for the discovery and 250 
discrimination of food intake biomarkers.  251 
In this work, up to 70 and 30 phenolic metabolites have been identified and quantified 252 
in 24-h urine and fasting plasma samples, respectively, at baseline and after RW, DRW 253 
and gin interventions using a UPLC-MS/MS targeted analysis. Only 19 metabolites of 254 
(epi)catechin, methyl(epi)catechin and DHPV, 10 phenolic acids and resveratrol 255 
metabolites resulted in being higher in urine after RW and DRW compared with 256 
baseline or gin periods (Table 1). No differences were observed between RW and DRW 257 
metabolites in plasma and urine except for urinary concentrations of ethylgallate and its 258 
metabolites, whose concentration increased after the RW period (P<0.001). Ethylgallate 259 
is a wine compound derived from ethanol and gallic acid esterification [20], with similar 260 
concentration values in both wines (Supporting Information Table S1). The increment 261 
observed after RW intake may be due to the fact that ethylgallate could also be formed 262 
in the organism influenced by ethanol and gallate consumption through ethyl 263 
esterification by human esterases or by microbial metabolism [21, 22]. Up to this point, 264 
the results have shown individual statistical differences for metabolites between groups 265 
or the baseline time period. Previous targeted studies on the metabolism of polyphenols 266 
have also used these kind of approaches to evaluate statistical differences between 267 
groups in searching for polyphenol biomarkers [14, 17, 23] and sometimes they only 268 
focused on a few metabolites that could not represent the global fingerprint [14].  269 
In this study, the metabolites that displayed significant differences between both wine 270 
interventions and the baseline or gin period were selected as metabolite biomarker 271 
candidates to be evaluated in the stepwise logistic regression analysis. This approach, 272 
14 
 
 
traditionally used in clinical diagnosis [24], allows the identification of combinations of 273 
metabolites from several origins that increased their discriminate power regarding single 274 
metabolites. To our knowledge, this approach has been applied for the first time in 275 
targeted studies of polyphenol food research. Advantages over previous works were the 276 
high number of metabolites quantified that were added to this new step, which allowed 277 
the discrimination of those metabolites as better predictors of wine intake.  278 
All of the metabolites included in the model (Table 3) could come from the microbial 279 
degradation of several wine phenolics [11] and some of them are also present in wine 280 
composition, such as gallic acid, ethylgallate and 2,4-dihydroxybenzoic acid [16, 25, 281 
26]. Gallic acid could also be released from several compounds present in wine, such as 282 
gallates and anthocyanins [14, 27]. 2,4-Dihydroxybenzoic acid has also been described 283 
as coming from the degradation of anthocyanins [28] and 3-hydroxyphenylacetic and p-284 
coumaric acids, derived from procyanidins and anthocyanins, respectively [18, 29], 285 
which can be found in high content in wine [25]. Other analysed phenolic acids were 286 
not considered in the model since they were less discriminant as most arise from several 287 
food compounds. Thus, these metabolites could be misleading if they were considered 288 
as biomarkers, as has previously been suggested after the intake of berries [11, 30].  289 
Once the model for each kind of sample was obtained, the AUC, sensitivity and 290 
specificity and ROC curves evaluated their capacity to discriminate wine consumers. In 291 
addition, these values were compared with those corresponding to phenolic metabolite 292 
groups (Table 4 and Supporting Information Fig. S2). The resveratrol biomarker and 293 
microbial resveratrol metabolites had similar values to the model, with AUC values of 294 
96.5 and 98.8%, respectively. Until now, phase II metabolites of resveratrol have been 295 
proposed as good biomarkers of wine intake [12, 13], but microbial-derived metabolites 296 
have not been evaluated before. As was discussed above, one of the characteristics of a 297 
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good biomarker is being specific to food intake, thus resveratrol is well known for being 298 
almost exclusively distributed in grape products [31]. The fact to validate biomarkers is 299 
of great importance since there is the need for objective measures of food exposure that 300 
allow accurate measures taking into account their bioavailability [32]. Other phenolic 301 
groups with good but lower AUC values than the model were ethylgallate and gallic 302 
acid metabolites (Table 4). Thus, they could also be considered as biomarkers of wine 303 
intake. Previously, some authors positively associated gallic acid and methylgallic acid 304 
with the consumption of wine [33], but, to our knowledge, no associations have been 305 
published for ethylgallate. Gallic acid has even been described as the main metabolite of 306 
ethylgallate, with longer Tmax and t1/2 than its parent compound [34]. Both ethylgallate 307 
and gallic acid have been described in other foods, such as grape products, wine and 308 
vinegar, and tea, nuts and berries [25]. Other metabolites such as (epi)catechin and 309 
valerolactones were less discriminant than those described metabolites and the model. 310 
Although the concentrations of flavan-3-ols are high in wine, they are not exclusively of 311 
wine since metabolites have been described after cocoa, tea or nut consumption [18, 35, 312 
36]. As far as we know, previous studies have evaluated a single or groups of 313 
metabolites as biomarkers of specific food consumption. Therefore, as commented 314 
above, a same biomarker could be associated to different foods. Here, the application of 315 
this targeted metabolomic approach allows to define a specific biomarker imprinting of 316 
wine intake. 317 
The type of sample matrix in which biomarkers are measured also influences biomarker 318 
evaluation [37]. Twenty-four hour urine has been described as the gold standard sample 319 
for biomarker evaluation [38] and it provides a better measure of total polyphenol 320 
metabolites than fasting plasma as it provides a better index of intake [1]. However, for 321 
practical reasons, 24-h urine is not an easy sample to obtain in large-scale 322 
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epidemiological studies [1]. Consequently, we have assessed that fasting plasma should 323 
be considered for biomarker determination. In this study, individual and phenolic 324 
metabolite groups along with the score obtained from the prediction model (Supporting 325 
Information Fig. S3) were correlated between fasting plasma and 24-h urine (Table 5). 326 
The best correlations were observed among model scores from hydrolyzed and non-327 
hydrolyzed samples, indicating that those volunteers that were better classified as wine 328 
consumers were done so through both urine and plasma samples (r=0.565 and r=0.599, 329 
respectively P<0.001). Valerolactones and gallic acid microbial metabolites that also 330 
had significant correlations were selected for their important role as biomarkers in urine, 331 
and possible presence in fasting plasma due to their longer half-life [34, 36]. 332 
Ethylgallate could not be evaluated due to the low concentrations obtained in plasma 333 
since the Tmax and half-lives of ethylgallate were expected to be lower than its main 334 
metabolite gallic acid [34]. Although the coefficients of correlation were significant, the 335 
r values were clinically moderate (r < 0.750) [37], which was similar to previous studies 336 
that correlated urinary and plasma alkylresorcinol metabolites [37]. Correlations 337 
between 24-h urine and fasting plasma have been previously described for total 338 
flavonols in a crossover trial with a low flavonoid diet or with the same diet 339 
supplemented with flavonols (r=0.624) [39], as well as for isoflavones, using spot 340 
plasma (r=0.99) [40]. These correlations could open the possibility of finding those 341 
metabolites in plasma and establishing them as biomarkers of consumption and effect, 342 
but larger studies in a free-living population are needed to confirm and generalize this 343 
statement. In addition, a problem with the fasting plasma, as suggested previously [41], 344 
could be the substantial number of concentrations that are lower than the limit of 345 
quantification due to the short half-lives of polyphenol metabolites. 346 
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This study proposes the use of a quantitative targeted metabolomics approach that 347 
combines phenolic and microbial analysis, logistic regression joining with ROC curves 348 
in interventional studies to identify, evaluate and compare single, groups of biomarkers 349 
and the biomarker imprinting of wine intake. Correlations between fasting plasma and 350 
urine provide the opportunity to discriminate metabolites that could be good urinary 351 
biomarkers of consumption, both in urine and plasma. This approach is a promising tool 352 
that has great potential for identifying possible food biomarkers to evaluate compliance 353 
in clinical studies, identify eating patterns and make associations between polyphenol 354 
consumption and health benefits. 355 
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Table 1. Urinary concentrations of phenolic metabolites in 36 subjects at baseline and after the three intervention periods.a 
 
Metabolites MRM 
Urine samples (μmol, 24-h) b 
BAS RW DRW GIN P 
c 
 
Hydroxybenzoic acids       
4-Hydroxybenzoic acid 137/93 25.79±2.21a 29.84±3.52a,b 34.30±2.81b 27.07±2.21a 0.006 
3-Hydroxybenzoic acid 137/93 3.77±1.27a,b 4.11±0.89a,b 5.67±1.57b 2.97±0.9a 0.001 
2,4-Dihydroxybenzoic acid 153/109 1.57±0.17
a
 2.47±0.35
b
 2.67±0.37
b
 1.62±0.22
a
 <0.001 
2,6-Dihydroxybenzoic acid 153/109 6.19±0.6a 8.35±0.91b 8.74±0.88b 6.08±0.59a <0.001 
2,5-Dihydroxybenzoic acid 153/109 16.23±1.65a 24.79±2.91b 27.29±2.9b 17.2±2.2a <0.001 
3,5-Dihydroxybenzoic acid 153/109 3.93±0.66a,c 6.41±1.01a,b 7.57±1.26b 3.97±0.72c 0.006 
Protocatechuic acid 153/109 12.10±1.15 13.07±1.27 14.45±1.66 11.29±1.19 0.09 
Syringic acid 197/121 0.73±0.15a 1.91±0.43b 2.03±0.32b 0.70±0.17a <0.001 
4-Hydroxyhippuric acid 194/100 54.05±5.42 58.83±4.47 72.13±9.02 53.63±5.69 0.09 
3-Hydroxyhippuric acid 194/150 192.30±39.81 204.09±38.07 237.58±54.21 169.25±34.57 0.19 
Gallic acid metabolites        
Gallic acid 169/125 0.85±0.18
a 5.61±0.49b 4.76±0.53b 0.73±0.17a <0.001 
Methylgallic acid  e 167/108 2.97±0.42
a 4.37±0.62b 4.76±0.68b 3.03±0.41a <0.001 
Methylgallic sulfated,e 263/183 2.97±0.74
a 24.8±5.64b 19.94±3.08b 2.00±0.60a <0.001 
Ethylgallate metabolites 
 
       
Ethylgallate 197/169 1.06±0.37a 8.19±0.93b 4.97±0.73c 0.22±0.09a <0.001 
Ethylgallate sulfate
 d,e
 277/197 2.16±0.76
a
 24.18±2.73
b
 15.81±1.64
c
 0.36±0.14
a
 <0.001 
Ethylgallate glucuronide 1 d,e 373/197 36.73±6.01a 176.89±20.38b 114.52±10.77b 31.49±5.43a <0.001 
Ethylgallate glucuronide 2  d,e 
d,e 
373/197 101.74±22.4a 366.5±37.6b 240.9±24.23c 64.5±5.75a <0.001 
Hydroxyphenylacetic acids       
Phenylacetic acid 135/91 22.15±2.21a,b 25.49±2.40a,b 27.66±3.00a 21.31±2.17b 0.005 
3-Hydroxyphenylacetic acid 151/107 24.72±3.50a 52.27±6.76b 56.57±6.9b 19.74±2.51a <0.001 
2-Hydroxyphenylacetic acid 151/107 5.89±0.40a,b 6.48±0.55a,b 7.41±0.54b 5.76±0.49a 0.008 
3,4-Dihydroxyphenylacetic acid 167/123 1.61±0.17a 1.98±0.17a,b 2.37±0.24b 2.12±0.32a,b 0.026 
Homovanillic acid 181/137 164.35±13.99 185.49±21.12 215.13±25.55 166.92±23.28 0.09 
Hydroxycinnamic acids       
m-Coumaric acid 163/119 0.54±0.09a,b 0.86±0.20a 0.83±0.20a,b 0.40±0.06b 0.005 
p-Coumaric acid 163/119 0.64±0.07a 1.75±0.35b 1.48±0.15b 0.55±0.08a <0.001 
23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
BAS, baseline; DRW, dealcoholized red wine; DHPV, dihydroxyphenyl-γ-valerolactone; MHPV, methoxyhydroxyphenyl-γ-valerolactone; MRM, Multiple Reaction Monitoring; RW, red wine. 
o-Coumaric acid 163/119 0.07±0.02 0.11±0.05 0.10±0.03 0.13±0.03 0.19 
Caffeic acid 179/135 5.42±0.34a 5.84±0.47a,b 7.05±0.55b 4.83±0.45a <0.001 
Ferulic acid 193/134 11.80±0.98
a 15.7±1.79a,b 15.25±0.94b 11.16±0.83a 0.002 
Sinapic acid 223/164 0.99±0.18 1.25±0.19 1.43±0.2 1.18±0.26 0.091 
Hydroxyphenylpropionic acids       
3-(3-Hydroxyphenyl) propionic acid 165/121 6.22±1.09a 7.13±1.26a,b 10.07±2.05b 4.70±0.87a <0.001 
3-(4-Hydroxyphenyl)propionic acid 165/121 287.44±27.16 371.63±45.16 389.2±39.36 313.3±36.76 0.06 
Dihydrocaffeic acid 181/137 14.09±1.39a,b 16.22±1.75a,b 17.29±1.50b 12.87±1.51a 0.018 
Flavan-3-ols
 e
       
∑(Epi)catechin glucuronidesd 465/289 9.42±1.58
a 24.15±3.20b 26.61±5.39b 6.72±1.87a <0.001 
∑ (Epi)catechin sulfatesd 369/289 3.04±0.49
a 10.17±1.44b 10.69±1.66b 2.50±0.44a <0.001 
∑ Methyl(epi)catechin glucuronidesd 479/303 3.76±0.93
a 15.95±2.41b 13.84±2.74b 3.32±0.84a <0.001 
∑ Methyl(epi)catechin sulfatesd 383/303 10.87±1.94
a 25.27±2.92b 25.64±3.39b 7.33±1.9a <0.001 
Glycinates       
Vanilloylglycine 224/180 0.80±0.09
a 1.41±0.26b 1.31±0.16a,b 0.80±0.13a 0.001 
Feruloylglycine 250/100 9.23±1.05 11.27±1.38 11.24±1.31 8.88±1.35 0.14 
Hydroxyphenylvalerolactones
e
       
DHPV 1 207/163 6.73±1.21a 13.80±2.78b 13.61±2.68b 3.67±0.77a <0.001 
DHPV 2 207/163 18.50±3.67a 34.20±5.59b 37.04±4.31b 7.80±1.97c <0.001 
∑ DHPV glucuronides d 383/207 70.62±14.54
a 157.76±27.06b 177.49±24.62b 36.52±8.84a <0.001 
∑ DHPV sulfatesd 287/207 527.13±55.87
a 876.9±101.81b 913.43±114.12b 418.39±71.73a <0.001 
MHPV 221/162 ND ND ND ND  
MHPV glucuronide
 d
 397/221 23.81±4.43
a,c
 37.36±6.57
a,b
 38.43±7.08
b
 20.24±4.19
c
 <0.001 
∑MHPV sulfates d 301/221 32.29±5.52
a,b 38.42±6.12a,b 43.13±6.52b 24.9±4.26a 0.006 
Stilbenes
 d,f
       
Resveratrol Biomarker g - 692.21±208.33a 5352.45±661.99b 5824.25±722.19b 238.00±84.61a <0.001 
∑Resveratrol Microbial Metabolites - 506.39±107.97
a 4208.95±430.76b 5230.62±508.44b 283.86±76.23a <0.001 
∑Total resveratrol metabolites - 811.54±211.27
a 6282.25±770.39b 7090.29±822.66b 306.08±90.44a <0.001 
Other polyphenols       
Enterolactone 297/254 8.73±1.10a 11.4±2.19a,b 14.81±3.40b 7.82±0.94a 0.001 
Pyrogallol 125/69 1.96±0.43a 8.00±1.19b 8.08±1.78b 2.99±0.58a <0.001 
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b 
Results are expressed as mean ± SEM.  
c 
Changes in variables were determined by using the ANOVA analysis for repeated measures. Means in a row with different superscript letters are significantly different, P < 0.05 (Bonferroni 
post hoc test).  
d 
Metabolites determined in non-hydrolyzed samples. 
e 
Identification of metabolites described previously by Boto-Ordoñez et al.[16] 
f
 Data obtained from a previous study by Rotches-Ribalta et al.[15] 
g
 Resveratrol Biomarker described by Zamora-Ros et al.[12].  
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Table 2. Fasting plasma concentrations of metabolites in 33 subjects at baseline and after the three intervention periods.
a 
 
Metabolites MRM Plasma samples (μmol/L) b  
BAS RW DRW GIN P 
c
 
Hydroxybenzoic acids       
4-Hydroxybenzoic acid 137/93 3.26±0.14 3.47±0.12 3.44±0.09 3.02±0.17 0.22 
3-Hydroxybenzoic acid 137/93 ND ND ND ND  
2,4-Dihydroxybenzoic acid 153/109 ND ND ND ND  
2,6-Dihydroxybenzoic acid 153/109 0.08±0.01 0.10±0.01 0.10±0.01 0.08±0.01 0.38 
2,5-Dihydroxybenzoic acid 153/109 0.04±0.01 0.05±0.01 0.07±0.02 0.03±0.01 0.08 
3,5-Dihydroxybenzoic acid 153/109 ND ND ND ND  
Protocatechuic acid 153/109 1.74±0.06 1.74±0.08 1.86±0.08 1.69±0.07 0.73 
Syringic acid 197/121 ND ND ND ND  
4-Hydroxyhippuric acid 194/100 0.17±0.02 0.16±0.02 0.17±0.02 0.15±0.01 0.85 
3-Hydroxyhippuric acid 194/150 0.85±0.53 1.03±0.45 1.21±0.62 0.69±0.32 0.89 
Gallic acid metabolites       
Gallic acid 169/125 0.02±0.001a 0.04±0.005b 0.03±0.002a,b 0.02±0.002a <0.001 
Methylgallic acid e 167/108 0.04±0.004a 0.07±0.02b 0.06±0.01a,b 0.04±0.01a 0.037 
Methylgallic sulfate d,e 263/183 0.002±0.0004a 0.02±0.004b 0.01±0.002b 0.001±0.0003a <0.001 
Ethylgallate metabolites       
Ethylgallate  197/169 0.03±0.01 0.04±0.01 0.09±0.06 0.03±0.02 0.93 
Ethylgallate sulfate d,e 277/197 ND ND ND ND  
Ethylgallate glucuronide 1 d,e 373/197 0.10±0.018.9 0.36±0.21 0.12±0.03 0.17±0.07 0.16 
Ethylgallate glucuronide 2 d,e 373/197 0.09±0.011.63 0.11±0.02 0.10±0.01 0.09±0.02 0.45 
Hydroxyphenylacetic acids       
Phenylacetic acid 135/91 0.37±0.03 0.38±0.03 0.38±0.03 0.36±0.04 0.76 
3-Hydroxyphenylacetic acid 151/107 0.22±0.03a 0.38±0.06b,c 0.40±0.04b 0.24±0.04a,c 0.002 
2-Hydroxyphenylacetic acid 151/107 0.08±0.01 0.10±0.01 0.10±0.01 0.08±0.01 0.33 
3,4-Dihydroxyphenylacetic acid 167/123 0.03±0.01 0.03±0.01 0.03±0.01 0.02±0.01 0.80 
Homovanillic acid 181/137 ND ND ND ND  
Hydroxycinnamic acids       
p-Coumaric acid 163/119 0.005±0.002a 0.02±0.003b 0.02±0.003b 0.02±0.003b <0.001 
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m-Coumaric acid 163/119 ND ND ND ND  
o-Coumaric acid 163/119 ND ND ND ND  
Caffeic acid 179/135 0.09±0.01 0.09±0.01 0.11±0.01 0.08±0.01 0.19 
Ferulic acid 193/134 1.63±0.06 1.65±0.06 1.69±0.06 1.55±0.04 0.56 
Sinapic acid 223/164 ND ND ND ND  
Hydroxyphenylpropanoic acids       
3-(4-Hydroxyphenyl)propionic acid 165/121 3.34±0.17 3.44±0.23 3.54±0.17 3.05±0.24 0.30 
3-(3-Hydroxyphenyl)propionic acid 165/121 0.21±0.05 0.21±0.05 0.29±0.06 0.15±0.04 0.14 
Dihydrocaffeic acid 181/137 ND ND ND ND  
Flavan-3-ols 
e       
(Epi)catechin glucuronide
4
 465/289 0.02±0.01
a
 0.05±0.01
b
 0.04±0.01
b
 0.02±0.01
 a
 <0.001 
Methyl(epi)catechin glucuronide4 479/303 0.01±0.001a,c 0.03±0.01b 0.02±0.01a,b 0.01±0.001c 0.004 
Glycynates       
Vanilloylglycine 224/180 0.03±0.001 0.03±0.001 0.03±0.001 0.03±0.001 0.24 
Feruloylglycine 250/100 0.08±0.002 0.09±0.003 0.09±0.003 0.08±0.003 0.44 
Hydroxyphenylvalerolactones 
e
       
DHPV 1 207/163 0.07±0.02a,c 0.16±0.03b 0.10±0.02a,b 0.04±0.02c <0.001 
DHPV 2 207/163 0.17±0.04a,c 0.45±0.1b 0.29±0.06a,b 0.10±0.03c <0.001 
∑ DHPV glucuronidesd 383/207 0.18±0.05a,b 0.46±0.13b 0.29±0.06a,b 0.14±0.08a <0.001 
∑ DHPV sulfates d 287/207 ND ND ND ND  
MPHV 221/162 ND ND ND ND  
MHPV glucuronide d 397/221 ND ND ND ND  
∑ MPHV sulfates d 301/221 ND ND ND ND  
Other polyphenols       
Enterolactone 297/254 0.01±0.002 0.01±0.002 0.02±0.01 0.01±0.002 0.18 
Pyrogallol 125/69 ND ND ND ND  
a 
BAS, baseline; DRW, dealcoholized red wine; DHPV, dihydroxyphenyl-c-valerolactone; MHPV, Methoxy-hydroxyphenyl-valerolactone; MRM, Multiple Reaction Monitoring; ND, no 
detected; RW, red wine. 
b 
Results are expressed as mean ± SEM. 
c 
Changes in variables were determined by using the ANOVA analysis for repeated measures. Means in a row with different 
superscript letters are significantly different, P < 0.05 (Bonferroni post hoc test). d Metabolites determined in non-hydrolyzed samples. e Identification of metabolites described previously by 
Boto-Ordoñez et al. [16] 
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Table 3. Urine and plasma metabolites in hydrolyzed and non-hydrolyzed samples 
selected by the stepwise logistic regression model for discriminating wine consumers 
obtained from the training set 
 
 
 
Coefficient Standard error p value 
Coefficient  
CI 95% 
URINE      
Hydrolyzed samples     
2,4-Dihydroxybenzoic Acid 0.60 0.23 0.007 0.16, 1.05 
Gallic Acid 0.84 0.24 <0.001 0.38, 1.31 
Ethylgallate 0.48 0.18 0.009 0.12, 0.83 
Constant -4.47 0.94 <0.001 -6.31, -2.63 
Non-Hydrolyzed samples     
Methylgallic Acid Sulfate 0.17 0.06 0.005 0.05, 0.29 
Ethylgallate Sulfate 0.41 0.10 <0.001 0.21, 0.62 
Constant -4.19 0.91 <0.001 -5.98, -2.41 
PLASMA     
Hydrolyzed samples     
3-Hydroxyphenylacetic Acid 2.38 1.02 0.020 0.39, 4.38 
Gallic Acid 62.21 22.41 0.006 18.29, 106.12 
p-Coumaric Acid 40.91 15.43 0.008 10.67, 71.14 
Constant -3.09 0.79 <0.001 -4.64, -1.54 
Non-Hydrolyzed samples     
Methylgallic Acid Sulfate 525.00 118.68 <0.001 292.39, 757.61 
Constant -1.63 0.35 <0.001 -2.32, -0.94 
28 
 
 
Table 4. Threshold (cut-off), sensitivity, specificity, AUC and confidence interval of 
phenolic metabolite group biomarkers and the prediction model  
 
  
Threshold 
a
 
 
Sensitivity 
(%) 
Specificity 
(%) 
AUC 
 (%) 
AUC 95% 
CI  
 (%) 
URINE      
Hydrolyzed samples      
Gallic Acid Metabolites 4.89 88.89 77.80 87.75 81.97, 93.53 
DHPV Metabolites 18.17 83.33 66.70 81.15 74.14, 88.17 
Phenolic Acid Metabolites 207.2 69.44 62.50 71.95 64.03, 80.34 
Ethylgallate 0.69 93.06 84.72 92.35 87.73, 96.97 
Training Set   94.74 91.23 96.24 92.73, 99.76 
Validation Set   93.33 93.33 96.00 89.24, 100.0 
All population    91.66 91.66 96.14 93.12, 99.16 
Non-hydrolyzed samples 
 
     
(Epi)catechin Metabolites 39.84 75.00 83.33 86.32 80.38, 92.27 
DHPV Metabolites 695.53 66.70 73.60 76.33 68.70, 83.96 
Ethylgallate Metabolites 152.31 98.60 84.70 93.67 89.49, 97.86 
Methylgallic Sulfate 5.49 87.50 86.11 93.23 89.31, 97.15 
Resveratrol Biomarker  1966.05 91.67 95.83 96.45 93.38, 99.52 
Resveratrol Microbial Metabolites 1424.19 95.83 93.06 98.77 97.46, 100.0 
Training Set   94.74 96.49 98.68 97.13, 100.0 
Validation Set   100.0 93.33 96.44 89.32, 100.0 
All population    95.83 94.44 98.40 96.80, 100.0 
PLASMA      
Hydrolyzed samples      
Gallic Acid Metabolites 0.06 68.18 57.58 64.10 54.66, 73.53 
DHPV Metabolites 0.14 68.18 62.12 68.37 59.31, 77.42 
Phenolic Acid Metabolites 0.24 72.73 65.15 68.02 58.88, 77.16 
Training Set   74.07 76.92 80.13 71.75, 88.51 
Validation Set   75.00 100.0 88.10 74.20, 100.0 
All population    75.76 74.24 81.18 73.86, 88.49 
Non-hydrolyzed samples      
(Epi)catechin Metabolites 0.03 69.70 75.76 76.92 68.76, 85.07 
DHPV Metabolites 0.06 72.73 62.12 71.12 62.37, 79.87 
Methylgallic Sulfate 0.002 84.85 77.27 87.50 81.65, 93.35 
Training Set   85.19 76.92 86.89 80.13, 93.66 
Validation Set   91.67 78.57 91.07 80.22, 100.0 
All population    84.85 77.27 87.50 81.65, 93.35 
 
DHPV, dihydroxyphenyl-γ-valerolactone; ROC, receiver operating characteristic. 
a 
Urine (µmol/24-h) or plasma (µmol/L). 
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Table 5. Spearman’s correlations between fasting plasma and 24-h urine samples for 
individual, phenolic metabolite groups and the prediction model 
 
  
 
 R P 
Hydrolyzed samples   
Gallic acid 0.338 <0.001 
3-Methylgallic acid 0.441 <0.001 
Gallic acid group 0.451 <0.001 
   
2,5-Dihydroxybenzoic acid 0.411 <0.001 
Protocatechuic acid 0.174 0.046 
3-(3-Hydroxyphenyl)propionic acid 0.402 <0.001 
Ferulic acid 0.253 0.003 
4-Hydroxyhippuric acid 0.310 <0.001 
3-Hydroxyphenylacetic acid 0.444 <0.001 
2-Hydroxyphenylacetic acid 0.204 0.019 
Enterolactone 0.503 <0.001 
p-Coumaric acid 0.370 <0.001 
Phenolic acid group 0.442 <0.001 
   
DHPV1 0.321 <0.001 
DHPV2 0.336 <0.001 
DHPV group 0.348 <0.001 
   
Prediction model score 0.565 <0.001 
   
Non-hydrolyzed samples   
Methylgallic acid sulfate 0.587 <0.001 
   
(Epi)catechin glucuronide 3 0.342 <0.001 
Methyl (epi)catechin glucuronide 2 0.294 0.001 
Flavan-3-ol group 0.382 <0.001 
   
DHPV1 Glucuronide 0.321 <0.001 
DHPV2 Glucuronide 0.342 <0.001 
DHPV Group 0.356 <0.001 
   
Prediction model score 0.599 <0.001 
